The EU's Top Valsartan Lesson: Closely Examine Active Substance Manufacturing Processes
EU report on “lessons learnt” from the valsartan crisis calls for tighter GMP controls on API suppliers.
You may also be interested in...
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The US FDA has issued a draft question and answer document to the ICH M7 guideline that sheds some light on the validation that needs to be performed before manufactures can rely on the results of computational tests in assessing genotoxic impurities of new drugs.
Agency guidance establishes process for ridding unsafe levels of the probable carcinogens from the pharmaceutical supply chain.